CDK4 and neoplasm: Several preclinical studies have recently reported the ability of CDK4/6i to induce anti-tumor immune responses [74,75] by enhancing tumor antigen presentation major histocompatibility complex (MHC), increasing production of type III interferons, and by reducing the proliferation of immune-suppressive regulatory T-cells (Treg-cells) [74].